VAX-31 Clears Phase 3 Bar, But 2028 BLA Timeline Hands Entrenched Rivals a Multi-Year Head Start

Vaxcyte's VAX-31 Achieves All Primary Endpoints in Pivotal Phase 3 OPUS-1 Trial

Vaxcyte announced positive topline results from its pivotal adult Phase 3 OPUS-1 trial evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older, demonstrating noninferiority for 28 serotypes shared with PCV20 and/or PCV21, and superiority for three unique serotypes and cross-reactive serotype 20B. It also met the primary immunobridging endpoint in adults aged 18-49 compared to adults aged 50-64 for all 321 serotype comparisons. The vaccine was well tolerated with a safety profile similar to comparators. These results will serve as the cornerstone for a planned Biologics License Application (BLA) submission in the first half of 2028.

• VAX-31 achieved all prespecified co-primary immunogenicity endpoints in adults 50 and older. This included meeting noninferiority criteria (LBCI >0.667) for all 28 serotypes shared with PCV20 and/or PCV21, and demonstrating superiority (LBCI >2.0) for the three serotypes unique to VAX-31 and cross-reactive serotype 20B. This comprehensive success across shared and unique serotypes underscores the vaccine's broad protective potential.
• The OPUS-1 trial successfully met its prespecified primary immunobridging endpoint, showing noninferiority (LBCI >0.667) for all 321 serotype OPA GMR comparisons in adults aged 18-49 compared to adults aged 50-64. Furthermore, VAX-31 exhibited a safety and tolerability profile similar to PCV20 and PCV21 across all age groups, with solicited reactions generally mild-to-moderate and no serious adverse events considered related to the study vaccines.
• VAX-31 is designed to offer broader coverage, with the potential to provide incremental protection against 13-36% of invasive pneumococcal disease and 19-31% of pneumococcal pneumonia compared to currently available adult PCVs. These positive OPUS-1 results are foundational for Vaxcyte's planned Biologics License Application (BLA) submission in the first half of 2028, with further Phase 3 results (OPUS-2 and OPUS-3) anticipated in the first half of 2027.

Why Broader Coverage is Crucial for Adult Pneumococcal Disease

Antimicrobial resistance and serotype replacement represent two converging pressures that complicate the clinical and strategic management of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. Current treatment approaches face mounting limitations across diagnostic, microbiological, and immunological dimensions, each with direct implications for patient outcomes and therapeutic decision-making.

• Escalating antimicrobial resistance in S. pneumoniae: Clinical isolates demonstrate universal penicillinase production (45/45, 100%), with complete beta-lactam resistance found in 42 of 45 isolates (93.3%), mediated through mutations in the pbp1a, pbp2x, and pbp2b genes. erm(B)-mediated macrolide resistance was observed in 37 of 45 isolates (82.2%), tetM-mediated tetracycline resistance in 37 of 45 isolates (82.2%), and fluoroquinolone resistance in 13 of 45 isolates (28.9%). One isolate demonstrated vancomycin resistance, underscoring the emergence of multidrug-resistant strains. Separately, minimum inhibitory concentrations of beta-lactams for S. pneumoniae have increased up to 100-fold in recent years, driven by alterations in penicillin-binding proteins — meaning higher penicillin MICs elevate MICs across all beta-lactams simultaneously. Macrolide resistance correlates with penicillin resistance, and because resistance mechanisms to tetracyclines, chloramphenicol, and macrolides share the same transposon, multi-antibiotic resistance in S. pneumoniae is common.

• Serotype replacement following conjugate vaccination: Seven-valent pneumococcal conjugate vaccine (PCV7) introduction reduced vaccine-type (VT) invasive pneumococcal disease substantially — by 98% in individuals younger than 2 years and 81% in those aged 65 years or older — but non-vaccine-type (NVT) disease increased by 68% in individuals younger than 2 years and 48% in those aged 65 years or older. Key replacement serotypes identified include 7F, 19A, and 22F. After vaccine introduction, more NVT serotypes increased in frequency than decreased, consistent with vaccine-induced replacement. The prevalence and pathogenicity of NVTs following universal PCV13 administration have caused widespread concern, with emerging and spreading NVTs now regarded as a focus for future serotype epidemiological surveillance and vaccine optimization.

• Biofilm-forming capacity of emerging NVT serotypes: Among 16 emerging non-PCV13 serotypes evaluated, serotypes 11A and 35B formed ≥45% of the biofilm produced by the non-encapsulated M11 strain — a level substantially exceeding the other 14 NVTs analyzed. Nasopharyngeal colonisation, an essential step in the development of S. pneumoniae-induced IPD, is associated with biofilm formation, and the high biofilm-forming potential of these serotypes warrants close surveillance given their capacity to sustain colonisation and facilitate invasive disease.

• Diagnostic misclassification and overlapping clinical syndromes: A significant percentage of pneumonia is misdiagnosed as septic shock, and the complex interplay of immune-molecular pathways underlying both sepsis and pneumonia results in similar and overlapping disease characteristics. Pneumococcal pneumonia can disseminate and induce systemic inflammation and severe sepsis, with S. pneumoniae potentially exploiting dendritic cell function to facilitate bacterial dissemination. The role of dendritic cells in pneumococcal infections and sepsis remains poorly understood, creating gaps in pathophysiological knowledge that complicate both clinical diagnosis and management.

• Host immune dysregulation as a driver of morbidity: An iron-dependent transcriptional regulator (IDTR) in S. pneumoniae modulates host cytokine response and systemic inflammation, contributing to morbidity and mortality of invasive pneumococcal disease. Since an exaggerated inflammatory response is associated with a poor prognosis in sepsis, the immunological crosstalk between pneumococcus and host immune mediators represents a critical — and insufficiently understood — dimension of disease management that current treatment strategies do not adequately address.

VAX-31's OPUS-1 Trial Design and Positive Topline Data

Several clinical trials and observational studies have examined pneumococcal conjugate vaccines (PCVs) across diverse populations, evaluating immunogenicity, schedule optimization, and clinical outcomes in the context of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. The studies span pediatric, adult, and high-risk populations, employing a range of designs from randomized controlled trials to retrospective observational analyses.

VAX-31's Competitive Advantage and Path to BLA

The treatment landscape for pneumococcal pneumonia and invasive pneumococcal disease (IPD) has evolved considerably, with both antibiotic and vaccine-based strategies informing the standard of care. Among antibiotic agents, lefamulin — a first-in-class semisynthetic pleuromutilin — was approved by the United States Food and Drug Administration and the European Commission in 2019 and 2020, respectively, for community-acquired bacterial pneumonia (CABP). Two Phase 3 Lefamulin Evaluation Against Pneumonia trials established non-inferiority of lefamulin against moxifloxacin in the treatment of CABP, including sequential intravenous-to-oral transition across a broad set of patient demographics and severities, with in vitro activity confirmed against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. Ceftaroline fosamil, a broad-spectrum cephalosporin active against both penicillin-nonsusceptible and multidrug-resistant S. pneumoniae as well as methicillin-resistant Staphylococcus aureus, demonstrated clinical cure rates of 88% (94/107 patients) in the ceftaroline fosamil group versus 89% (32/36 patients) in the ceftriaxone group at test-of-cure in a randomized, observer-blinded pediatric CABP study, with comparable tolerability between arms.

In the ICU setting, linezolid has been evaluated as both first- and second-line therapy for Gram-positive infections, including those caused by S. pneumoniae. In a multi-center, real-world observational study across 52 hospitals, clinical success was achieved in 301 of 366 (82.2%) critically ill patients, with 34 (9.3%) cured and 267 (73.0%) improved. Linezolid-related adverse events were reported in only 8 (2.2%) patients, and no treatment-related serious adverse events were recorded. For uncomplicated acute exacerbations of chronic bronchitis — a condition frequently driven by S. pneumoniae — double-blind randomized clinical trials published since 2000 demonstrated that extended-spectrum oral cephems cefdinir and cefditoren achieved similar point estimates of clinical cure and bacteriologic response compared with cefuroxime, cefprozil, or Locarbacef.

On the vaccine prevention front, the shift from sequential PCV13 and PPSV23 regimens toward higher-valent conjugate vaccines reflects the impact of serotype replacement in adult IPD and pneumococcal pneumonia since the 2000s. A prospective 5-year follow-up study in 26 kidney transplant recipients showed that mean IgG levels remained approximately threefold higher than pre-vaccination values at 5 years, with no cases of pneumococcal pneumonia during follow-up, though absolute titers remained considerably lower than those observed in healthy individuals. PCV21, a 21-valent conjugate vaccine comprising the 13 serotypes of PCV13 plus 8 additional serotypes, demonstrated favorable immunogenicity and an acceptable safety profile comparable with PCV13 in a randomized Phase 2 study in toddlers and infants, with numerically greater immunogenicity in PCV21 groups for the additional serotypes — supporting its evaluation in Phase 3 assessment.

31-Valent VAX-31: A Game Changer in Adult Pneumococcal Prevention

The recent positive topline results for Vaxcyte's VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, signal a potentially transformative moment in the fight against pneumococcal disease. With invasive pneumococcal disease (IPD) and pneumococcal pneumonia continuing to pose significant health threats, especially for older adults, the need for broader protection against evolving serotype diversity and serotype replacement is paramount. VAX-31's success in its pivotal Phase 3 OPUS-1 trial, demonstrating noninferiority for 28 serotypes shared with current high-valency vaccines and, notably, superiority for three unique serotypes and cross-reactive serotype 20B, positions it as a formidable contender.

This expanded coverage is a direct result of Vaxcyte's innovative eCRM carrier protein technology, which enables the inclusion of more serotypes while maintaining robust immunogenicity and a safety profile comparable to existing vaccines. The successful immunobridging data in adults aged 18-49 further broadens its potential utility, paving the way for a comprehensive adult vaccination strategy.

However, the path to market leadership is not without its challenges. While the clinical data is strong, securing favorable market access and reimbursement will be critical in a competitive landscape. Regulatory bodies and public health agencies will also closely examine the epidemiological relevance of the unique serotypes to inform vaccination policy. Furthermore, the inherent manufacturing complexity of a 31-valent vaccine using advanced conjugation technology could present supply chain risks. Despite these considerations, VAX-31's robust profile suggests it could significantly elevate the standard of care, offering unprecedented protection and reshaping future pneumococcal vaccination guidelines.